United Therapeutics Corporation (UTHR) PB Ratio: 4.37
Is United Therapeutics Corporation’s P/B ratio high or low?
United Therapeutics Corporation's P/B ratio of 4.37 is 68% above its 5-year average of 2.60, near the high end of its 5-year range (1.81–4.77).
36.18% above its 12-month average of 3.21.
UTHR PB Ratio Chart
UTHR Average PB Ratio Chart
UTHR Current vs Average PB Ratio Chart
UTHR PB Ratio Metrics
PB RATIO
4.37
PB RATIO AVG TTM
3.21
PB RATIO AVG 3Y
2.68
PB RATIO AVG 5Y
2.60
PB RATIO AVG 10Y
2.44
PB RATIO AVG 15Y
2.98
PB RATIO AVG 20Y
3.63
CURRENT VS TTM AVG
+36.18%
CURRENT VS 3Y AVG
+63.33%
CURRENT VS 5Y AVG
+68.14%
CURRENT VS 10Y AVG
+79.16%
CURRENT VS 15Y AVG
+46.73%
CURRENT VS 20Y AVG
+20.39%
UTHR Competitors' PB Ratio
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| United Therapeutics Corporation (UTHR) | $23.17B | 4.37 | 3.21 | 2.68 | 2.60 |
| Waters Corporation (WAT) | $23.17B | 1.91 | 8.21 | 13.89 | 32.22 |
| BioNTech SE (BNTX) | $22.90B | 1.06 | 1.14 | 1.16 | 2.45 |
| Mettler-Toledo International Inc. (MTD) | $22.86B | N/A | 1966.63 | 623.56 | 375.27 |
| Labcorp Holdings Inc. (LH) | $21.83B | 2.53 | 2.60 | 2.40 | 2.24 |
| Veeva Systems Inc. (VEEV) | $25.92B | 3.63 | 5.81 | 6.74 | 8.99 |
| Moderna, Inc. (MRNA) | $19.80B | 2.66 | 1.61 | 2.06 | 4.91 |
| DexCom, Inc. (DXCM) | $29.08B | 10.03 | 10.87 | 16.27 | 18.91 |
| Hologic, Inc. (HOLX) | $16.97B | 3.27 | 3.17 | 3.48 | 3.78 |
| Biogen Inc. (BIIB) | $29.53B | 1.59 | 1.34 | 1.77 | 2.39 |
P/B vs. its own history
At 4.37, P/B is richer than usual, sitting higher than 75% of its 20-year history.
20-year low
1.26
median
3.00
20-year high
11.58
Book Value Analysis
P/B Ratio
4.37
Market Price / Book Value per Share
United Therapeutics Corporation PB Ratio Formula & Definition
PB Ratio = Market Cap / Total Shareholders' Equity
The price-to-book ratio compares market capitalization to book value (shareholders' equity). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
United Therapeutics Corporation PB Ratio FAQ
- What is the P/B ratio for United Therapeutics Corporation (UTHR)?
- The P/B ratio for UTHR stock is 4.37.
- Is United Therapeutics Corporation's P/B ratio high or low?
- United Therapeutics Corporation's P/B ratio of 4.37 is 68% above its 5-year average of 2.60, near the high end of its 5-year range (1.81–4.77).
- What is the TTM average P/B ratio for United Therapeutics Corporation (UTHR)?
- The TTM average P/B ratio for UTHR stock is 3.21.
- What is the 3Y average P/B ratio for United Therapeutics Corporation (UTHR)?
- The 3Y average P/B ratio for UTHR stock is 2.68.
- What is the 5Y average P/B ratio for United Therapeutics Corporation (UTHR)?
- The 5Y average P/B ratio for UTHR stock is 2.60.
- What is the 10Y average P/B ratio for United Therapeutics Corporation (UTHR)?
- The 10Y average P/B ratio for UTHR stock is 2.44.
- What is the 15Y average P/B ratio for United Therapeutics Corporation (UTHR)?
- The 15Y average P/B ratio for UTHR stock is 2.98.
- What is the 20Y average P/B ratio for United Therapeutics Corporation (UTHR)?
- The 20Y average P/B ratio for UTHR stock is 3.63.
United Therapeutics Corporation PB Ratio History
| DATE | PB RATIO |
|---|---|
| 2026-06-12 | 4.37 |
| 2026-06-11 | 4.36 |
| 2026-06-10 | 4.35 |
| 2026-06-09 | 4.42 |
| 2026-06-08 | 4.36 |
| 2026-06-05 | 4.40 |
| 2026-06-04 | 4.38 |
| 2026-06-03 | 4.39 |
| 2026-06-02 | 4.32 |
| 2026-06-01 | 4.36 |
| 2026-05-29 | 4.45 |
| 2026-05-28 | 4.50 |
| 2026-05-27 | 4.57 |
| 2026-05-26 | 4.63 |
| 2026-05-22 | 4.55 |
| 2026-05-21 | 4.53 |
| 2026-05-20 | 4.51 |
| 2026-05-19 | 4.53 |
| 2026-05-18 | 4.54 |
| 2026-05-15 | 4.55 |
| 2026-05-14 | 4.61 |
| 2026-05-13 | 4.64 |
| 2026-05-12 | 4.65 |
| 2026-05-11 | 4.56 |
| 2026-05-08 | 4.52 |
| 2026-05-07 | 4.55 |
| 2026-05-06 | 4.77 |
| 2026-05-05 | 3.86 |
| 2026-05-04 | 3.92 |
| 2026-05-01 | 3.85 |
| 2026-04-30 | 3.86 |
| 2026-04-29 | 3.85 |
| 2026-04-28 | 3.84 |
| 2026-04-27 | 3.83 |
| 2026-04-24 | 3.83 |
| 2026-04-23 | 3.87 |
| 2026-04-22 | 3.88 |
| 2026-04-21 | 3.87 |
| 2026-04-20 | 3.87 |
| 2026-04-17 | 3.97 |
| 2026-04-16 | 3.92 |
| 2026-04-15 | 3.90 |
| 2026-04-14 | 3.91 |
| 2026-04-13 | 3.90 |
| 2026-04-10 | 3.86 |
| 2026-04-09 | 3.88 |
| 2026-04-08 | 3.93 |
| 2026-04-07 | 3.82 |
| 2026-04-06 | 3.78 |
| 2026-04-02 | 3.81 |
| 2026-04-01 | 3.85 |
| 2026-03-31 | 4.00 |
| 2026-03-30 | 3.97 |
| 2026-03-27 | 3.53 |
| 2026-03-26 | 3.59 |
| 2026-03-25 | 3.66 |
| 2026-03-24 | 3.59 |
| 2026-03-23 | 3.52 |
| 2026-03-20 | 3.54 |
| 2026-03-19 | 3.56 |
| 2026-03-18 | 3.58 |
| 2026-03-17 | 3.65 |
| 2026-03-16 | 3.61 |
| 2026-03-13 | 3.62 |
| 2026-03-12 | 3.60 |
| 2026-03-11 | 3.68 |
| 2026-03-10 | 3.62 |
| 2026-03-09 | 3.57 |
| 2026-03-06 | 3.23 |
| 2026-03-05 | 3.27 |
| 2026-03-04 | 3.31 |
| 2026-03-03 | 3.37 |
| 2026-03-02 | 3.47 |
| 2026-02-27 | 3.40 |
| 2026-02-26 | 3.40 |
| 2026-02-25 | 3.61 |
| 2026-02-24 | 3.40 |
| 2026-02-23 | 3.41 |
| 2026-02-20 | 3.40 |
| 2026-02-19 | 3.45 |
| 2026-02-18 | 3.42 |
| 2026-02-17 | 3.46 |
| 2026-02-13 | 3.40 |
| 2026-02-12 | 3.42 |
| 2026-02-11 | 3.42 |
| 2026-02-10 | 3.40 |
| 2026-02-09 | 3.40 |
| 2026-02-06 | 3.48 |
| 2026-02-05 | 3.44 |
| 2026-02-04 | 3.46 |
| 2026-02-03 | 3.43 |
| 2026-02-02 | 3.41 |
| 2026-01-30 | 3.37 |
| 2026-01-29 | 3.36 |
| 2026-01-28 | 3.35 |
| 2026-01-27 | 3.42 |
| 2026-01-26 | 3.40 |
| 2026-01-23 | 3.37 |
| 2026-01-22 | 3.39 |
| 2026-01-21 | 3.37 |
| 2026-01-20 | 3.36 |
| 2026-01-16 | 3.34 |
| 2026-01-15 | 3.39 |
| 2026-01-14 | 3.41 |
| 2026-01-13 | 3.42 |
| 2026-01-12 | 3.46 |
| 2026-01-09 | 3.47 |
| 2026-01-08 | 3.52 |
| 2026-01-07 | 3.62 |
| 2026-01-06 | 3.61 |
| 2026-01-05 | 3.51 |
| 2026-01-02 | 3.57 |
| 2025-12-31 | 3.50 |
| 2025-12-30 | 3.56 |
| 2025-12-29 | 3.61 |
| 2025-12-26 | 3.64 |
| 2025-12-24 | 3.69 |
| 2025-12-23 | 3.66 |
| 2025-12-22 | 3.69 |
| 2025-12-19 | 3.71 |
| 2025-12-18 | 3.64 |
| 2025-12-17 | 3.67 |
| 2025-12-16 | 3.59 |
| 2025-12-15 | 3.59 |
| 2025-12-12 | 3.55 |
| 2025-12-11 | 3.51 |
| 2025-12-10 | 3.48 |
| 2025-12-09 | 3.42 |
| 2025-12-08 | 3.44 |
| 2025-12-05 | 3.51 |
| 2025-12-04 | 3.47 |
| 2025-12-03 | 3.45 |
| 2025-12-02 | 3.40 |
| 2025-12-01 | 3.44 |
| 2025-11-28 | 3.49 |
| 2025-11-26 | 3.51 |
| 2025-11-25 | 3.49 |
| 2025-11-24 | 3.43 |
| 2025-11-21 | 3.41 |
| 2025-11-20 | 3.41 |
| 2025-11-19 | 3.42 |
| 2025-11-18 | 3.42 |
| 2025-11-17 | 3.39 |
| 2025-11-14 | 3.35 |
| 2025-11-13 | 3.32 |
| 2025-11-12 | 3.31 |
| 2025-11-11 | 3.30 |
| 2025-11-10 | 3.26 |
| 2025-11-07 | 3.22 |
| 2025-11-06 | 3.26 |
| 2025-11-05 | 3.21 |
| 2025-11-04 | 3.14 |
| 2025-11-03 | 3.15 |
| 2025-10-31 | 3.20 |
| 2025-10-30 | 3.26 |
| 2025-10-29 | 3.27 |
| 2025-10-28 | 2.80 |
| 2025-10-27 | 2.83 |
| 2025-10-24 | 2.82 |
| 2025-10-23 | 2.87 |
| 2025-10-22 | 2.84 |
| 2025-10-21 | 2.84 |
| 2025-10-20 | 2.91 |
| 2025-10-17 | 2.92 |
| 2025-10-16 | 2.91 |
| 2025-10-15 | 2.91 |
| 2025-10-14 | 2.92 |
| 2025-10-13 | 2.96 |
| 2025-10-10 | 2.96 |
| 2025-10-09 | 3.00 |
| 2025-10-08 | 3.02 |
| 2025-10-07 | 3.08 |
| 2025-10-06 | 3.05 |
| 2025-10-03 | 3.05 |
| 2025-10-02 | 2.99 |
| 2025-10-01 | 2.95 |
| 2025-09-30 | 2.82 |
| 2025-09-29 | 2.86 |
| 2025-09-26 | 2.91 |
| 2025-09-25 | 2.86 |
| 2025-09-24 | 2.95 |
| 2025-09-23 | 2.92 |
| 2025-09-22 | 2.79 |
| 2025-09-19 | 2.81 |
| 2025-09-18 | 2.76 |
| 2025-09-17 | 2.72 |
| 2025-09-16 | 2.68 |
| 2025-09-15 | 2.71 |
| 2025-09-12 | 2.73 |
| 2025-09-11 | 2.73 |
| 2025-09-10 | 2.67 |
| 2025-09-09 | 2.72 |
| 2025-09-08 | 2.66 |
| 2025-09-05 | 2.70 |
| 2025-09-04 | 2.56 |
| 2025-09-03 | 2.64 |
| 2025-09-02 | 2.73 |
| 2025-08-29 | 2.05 |
| 2025-08-28 | 2.07 |
| 2025-08-27 | 2.06 |
| 2025-08-26 | 2.08 |
| 2025-08-25 | 2.06 |
| 2025-08-22 | 2.10 |
| 2025-08-21 | 2.09 |
| 2025-08-20 | 2.06 |
| 2025-08-19 | 2.11 |
| 2025-08-18 | 2.11 |
| 2025-08-15 | 2.11 |
| 2025-08-14 | 2.10 |
| 2025-08-13 | 2.09 |
| 2025-08-12 | 2.03 |
| 2025-08-11 | 2.02 |
| 2025-08-08 | 2.03 |
| 2025-08-07 | 2.02 |
| 2025-08-06 | 2.04 |
| 2025-08-05 | 2.05 |
| 2025-08-04 | 1.97 |
| 2025-08-01 | 1.98 |
| 2025-07-31 | 1.85 |
| 2025-07-30 | 1.90 |
| 2025-07-29 | 2.12 |
| 2025-07-28 | 2.13 |
| 2025-07-25 | 2.17 |
| 2025-07-24 | 2.19 |
| 2025-07-23 | 2.18 |
| 2025-07-22 | 2.13 |
| 2025-07-21 | 2.09 |
| 2025-07-18 | 2.08 |
| 2025-07-17 | 2.12 |
| 2025-07-16 | 2.13 |
| 2025-07-15 | 2.09 |
| 2025-07-14 | 2.13 |
| 2025-07-11 | 2.11 |
| 2025-07-10 | 2.14 |
| 2025-07-09 | 2.15 |
| 2025-07-08 | 2.10 |
| 2025-07-07 | 2.07 |
| 2025-07-03 | 2.10 |
| 2025-07-02 | 2.11 |
| 2025-07-01 | 2.08 |
| 2025-06-30 | 2.05 |
| 2025-06-27 | 2.03 |
| 2025-06-26 | 2.03 |
| 2025-06-25 | 2.04 |
| 2025-06-24 | 2.07 |
| 2025-06-23 | 2.04 |
| 2025-06-20 | 2.08 |
| 2025-06-18 | 2.08 |
| 2025-06-17 | 2.05 |
| 2025-06-16 | 2.06 |
| 2025-06-13 | 2.02 |
| 2025-06-12 | 2.04 |
| 2025-06-11 | 1.97 |
| 2025-06-10 | 2.01 |
| 2025-06-09 | 2.34 |
| 2025-06-06 | 2.33 |
| 2025-06-05 | 2.28 |
| 2025-06-04 | 2.31 |
| 2025-06-03 | 2.31 |
| 2025-06-02 | 2.32 |
Showing the most recent 260 of 5,033 data points. The chart above shows the full history.
Related Metrics
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martine A. Rothblatt